Testing cadonilimab and regorafenib for liver cancer after other treatments fail
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate or advanced liver cancer that has been confirmed by a biopsy or meets specific clinical guidelines.
- Your liver cancer has gotten worse after treatment with camrelizumab and apatinib.
- Your liver function is good (Child-Pugh class A) and you are in generally good health (ECOG score 0-1).
- You have at least one tumor that can be measured on a scan.
- Your blood counts and organ function (kidneys, liver) are within safe limits as checked by blood tests.
- You have no serious bleeding problems, no uncontrolled fluid buildup in the belly or chest, and no history of liver transplant or brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests a new combination of three drugs for people with advanced liver cancer whose disease got worse after their first treatment. The goal is to see if this new mix can help control the cancer better and give patients more time.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.